Accentis nv ACCB
EURONEXT · Belgium · Finance
€0.02550.00 (0.00%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Lagardere has slipped in recent months, yet over the past three years the stock is still modestly ahead. This puts fresh attention on whether today's share price lines up with the earnings that support it. With the share now at €18.04, the real issue for you as an investor is how much of the underlying profit story is already in the price. The stock has gained 5.7% over the past three years, so anyone looking at Lagardere today is effectively judging whether that medium term climb is fully...
ACEA has rewarded patient shareholders over recent years, yet the share price has been softer lately, which naturally raises the question of whether the current valuation is still well supported by its earnings power. For anyone looking at the stock today, the key issue is how much of the past share price gain already reflects what the business is earning right now. Over the past 3 years the share price has climbed 129.0%, which puts real pressure on the question of how fully its earnings...
About 50% of Concentrix’s revenue is coming from business it earned since introducing AI tools three years ago.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.